Literature DB >> 3129988

In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

G V Doern1, T A Tubert.   

Abstract

The in vitro activities of 39 antimicrobial agents were assessed versus 74 clinical isolates of Branhamella catarrhalis. Resistance was observed only with penicillin and ampicillin and then only with beta-lactamase-producing strains. The results of in vitro susceptibility tests with agar dilution and broth microdilution procedures were found to be comparable. The results of broth tube macrodilution tests were, in general, one twofold-concentration increment higher.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3129988      PMCID： PMC172147          DOI： 10.1128/AAC.32.2.259

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Branhamella catarrhalis--an emerging human pathogen.

Authors:  G V Doern
Journal:  Diagn Microbiol Infect Dis       Date:  1986-03       Impact factor: 2.803

2.  In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

Authors:  S Alvarez; M Jones; S Holtsclaw-Berk; J Guarderas; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

3.  Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary infections.

Authors:  F Ahmad; D T McLeod; M J Croughan; M A Calder
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

Authors:  G V Doern; T Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

5.  Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis.

Authors:  G V Doern; K G Siebers; L M Hallick; S A Morse
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

6.  In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains.

Authors:  K G Sweeney; A Verghese; C A Needham
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

8.  Detection of beta-lactamase activity among clinical isolates of Branhamella catarrhalis with six different beta-lactamase assays.

Authors:  G V Doern; T A Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

9.  Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.

Authors:  T Farmer; C Reading
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Disk diffusion susceptibility testing of Branhamella catarrhalis with ampicillin and seven other antimicrobial agents.

Authors:  G V Doern; T Tubert
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191
  10 in total
  14 in total

1.  [Treatment results using cefixime for bacterial respiratory tract infections].

Authors:  L Leonhardt
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  [Cefixime therapy in sinusitis].

Authors:  W Jorde; M Schata
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 4.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

5.  Wound infection caused by Branhamella catarrhalis.

Authors:  L D Gray; R E Van Scoy; J P Anhalt; P K Yu
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

6.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 7.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

8.  Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards.

Authors:  P C Kibsey; R P Rennie; J E Rushton
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

9.  Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.

Authors:  H Wakebe; T Imada; H Yoneda; F Mukai; K Ohguro; K Ohmori; H Tamaoka; Y Yabuuchi
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

Authors:  F A Sarubbi; A Verghese; C Caggiano; S Holtsclaw-Berk; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.